Kuznicki Law is investigating Catalyst Biosciences, Inc. (NasdaqCM: CBIO) in connection with its acquisition of the F351 program, a next-generation fibrosis drug, from GNI Group Ltd. and, in a separate transaction, its acquisition of a controlling interest in Beijing Continent for 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock (Series X) with economic rights equivalent to Catalyst’s common stock. Each share of Series X preferred stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. Kuznicki Law is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.
Catalyst Biosciences, Inc. (NasdaqCM: CBIO) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.